{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T16:56:02Z","timestamp":1765558562149,"version":"3.48.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cardiac transthyretin amyloidosis (ATTR-CM) is an infiltrative cardiomyopathy leading to restrictive physiology and, in advanced stages, systolic dysfunction. Conventional heart failure therapy is often poorly tolerated, and Tafamidis access may be restricted in patients with reduced ejection fraction. Cardiac contractility modulation (CCM) enhances contractility and could represent an alternative in this setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case summary<\/jats:title>\n                    <jats:p>A 76-year-old man with wild-type transthyretin cardiac amyloidosis (ATTRwt) and mildly reduced left ventricular ejection fraction (LEVF 44%) developed persistent symptoms despite optimized medical therapy and enrolment in a clinical trial. Due to persistent systolic dysfunction (LVEF 43%), he was ineligible for Tafamidis reimbursement. A CCM device was implanted in March 2024, resulting in progressive improvement in LVEF to 54% by February 2025, enabling Tafamidis initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Wild-type transthyretin cardiac amyloidosis is underdiagnosed, and treatment options remain limited, particularly in patients with systolic dysfunction. Cardiac contractility modulation has demonstrated benefit in non-infiltrative cardiomyopathies, but evidence in amyloidosis is scarce. Our case represents the second documented worldwide, showing that CCM may improve ventricular function and clinical status and, importantly, may facilitate access to disease-modifying therapy. This report highlights CCM as a potential bridge strategy in selected patients with ATTR-CM and reduced ejection fraction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytaf608","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T13:28:49Z","timestamp":1763731729000},"source":"Crossref","is-referenced-by-count":0,"title":["Cardiac contractility modulation as a novel therapeutic approach in transthyretin amyloid cardiomyopathy to improve eligibility to stabilizer therapy: a case report"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0007-3248","authenticated-orcid":false,"given":"Arancha","family":"D\u00edaz Exp\u00f3sito","sequence":"first","affiliation":[{"name":"Heart Failure and Inherited Cardiac Diseases Unit, Virgen de la Victoria University Hospital , Campus Universitario de Teatinos s\/n, 29010 M\u00e1laga, Spain"},{"name":"Biomedical Research Institute of M\u00e1laga (IBIMA) , C\/Severo Ochoa 35, 29590 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro I","family":"P\u00e9rez Cabeza","sequence":"additional","affiliation":[{"name":"Heart Failure and Inherited Cardiac Diseases Unit, Virgen de la Victoria University Hospital , Campus Universitario de Teatinos s\/n, 29010 M\u00e1laga, Spain"},{"name":"Biomedical Research Institute of M\u00e1laga (IBIMA) , C\/Severo Ochoa 35, 29590 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paloma","family":"M\u00e1rquez Camas","sequence":"additional","affiliation":[{"name":"Heart Failure and Inherited Cardiac Diseases Unit, Virgen de la Victoria University Hospital , Campus Universitario de Teatinos s\/n, 29010 M\u00e1laga, Spain"},{"name":"Biomedical Research Institute of M\u00e1laga (IBIMA) , C\/Severo Ochoa 35, 29590 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ainhoa","family":"Robles Mezcua","sequence":"additional","affiliation":[{"name":"Heart Failure and Inherited Cardiac Diseases Unit, Virgen de la Victoria University Hospital , Campus Universitario de Teatinos s\/n, 29010 M\u00e1laga, Spain"},{"name":"Biomedical Research Institute of M\u00e1laga (IBIMA) , C\/Severo Ochoa 35, 29590 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Manuel","family":"Garc\u00eda Pinilla","sequence":"additional","affiliation":[{"name":"Heart Failure and Inherited Cardiac Diseases Unit, Virgen de la Victoria University Hospital , Campus Universitario de Teatinos s\/n, 29010 M\u00e1laga, Spain"},{"name":"Biomedical Research Institute of M\u00e1laga (IBIMA) , C\/Severo Ochoa 35, 29590 M\u00e1laga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"2025121211471231900_ytaf608-B1","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"2025121211471231900_ytaf608-B2","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2025121211471231900_ytaf608-B3","first-page":"523","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the heart failure association (HFA) of the ESC","volume":"75","author":"McDonagh","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2025121211471231900_ytaf608-B4","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jchf.2018.04.010","article-title":"A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation","volume":"6","author":"Abraham","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2025121211471231900_ytaf608-B5","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review","volume":"331","author":"Ruberg","year":"2024","journal-title":"JAMA"},{"key":"2025121211471231900_ytaf608-B6","doi-asserted-by":"crossref","first-page":"e022859","DOI":"10.1161\/JAHA.121.022859","article-title":"Lack of association between neurohormonal blockade and survival in transthyretin cardiac amyloidosis","volume":"10","author":"Cheng","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2025121211471231900_ytaf608-B7","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","article-title":"Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis","volume":"135","author":"Maurer","year":"2017","journal-title":"Circulation"},{"key":"2025121211471231900_ytaf608-B8","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2025121211471231900_ytaf608-B9","first-page":"724","article-title":"Clinical effects of cardiac contractility modulation (CCM) as a treatment for chronic heart failure","volume":"33","author":"Borggrefe","year":"2012","journal-title":"Eur Heart J"},{"key":"2025121211471231900_ytaf608-B10","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jacc.2008.01.036","article-title":"Cardiac contractility modulation electrical signals improve myocardial gene expression in patients with heart failure","volume":"51","author":"Butter","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2025121211471231900_ytaf608-B11","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrcardio.2013.114","article-title":"Cardiac contractility modulation therapy in advanced systolic heart failure","volume":"10","author":"Lyon","year":"2013","journal-title":"Nat Rev Cardiol"},{"key":"2025121211471231900_ytaf608-B12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/ejhf.1349","article-title":"Cardiac contractility modulation: mechanisms of action in heart failure with reduced ejection fraction and beyond","volume":"21","author":"Tsch\u00f6pe","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2025121211471231900_ytaf608-B13","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3390\/jcm12031184","article-title":"Cardiac contractility modulation therapy in patients with amyloid cardiomyopathy and heart failure, case report, review of the biophysics of CCM function, and AMY-CCM registry presentation","volume":"12","author":"Marchese","year":"2023","journal-title":"J Clin Med"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcr\/advance-article-pdf\/doi\/10.1093\/ehjcr\/ytaf608\/65552771\/ytaf608.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/9\/12\/ytaf608\/65552771\/ytaf608.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcr\/article-pdf\/9\/12\/ytaf608\/65552771\/ytaf608.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T16:47:17Z","timestamp":1765558037000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/doi\/10.1093\/ehjcr\/ytaf608\/8343658"}},"subtitle":[],"editor":[{"given":"Luca","family":"Monzo","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Niklas","family":"Schenker","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Ana","family":"Devesa","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Deepti","family":"Ranganathan","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,11,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytaf608","relation":{},"ISSN":["2514-2119"],"issn-type":[{"type":"electronic","value":"2514-2119"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,27]]},"article-number":"ytaf608"}}